Osteomyelitis Market Report 2026

The osteomyelitis market size has grown strongly in recent years. It will grow from $1.11 billion in 2025 to $1.21 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to increasing incidence of bone infections, rising prevalence of diabetes-related complications, growth in orthopedic surgical procedures, improved diagnostic imaging availability, expansion of hospital-based infection management.

The osteomyelitis market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing development of novel antibiotics, rising focus on antimicrobial resistance management, expansion of outpatient parenteral antibiotic therapy, growing investments in infection diagnostics, increasing demand for personalized treatment strategies. Major trends in the forecast period include increasing use of targeted antimicrobial therapies, rising adoption of long-term antibiotic regimens, growing focus on early infection diagnosis, expansion of multidisciplinary treatment approaches, enhanced emphasis on chronic infection management.

The rising incidence of chronic conditions is expected to drive the growth of the osteomyelitis market going forward. Chronic conditions are long-lasting health issues that persist for months or years and often require continuous management and care. The increase in chronic conditions is largely attributed to the aging global population, as advancing age weakens the immune system and increases susceptibility to long-term illnesses and infections. Chronic conditions elevate the risk of osteomyelitis by compromising immunity and reducing blood flow, particularly in diseases such as diabetes and vascular disorders. These conditions create an environment conducive to persistent infections, raising the likelihood of bone involvement and complicating recovery. For instance, in August 2023, according to a survey by the Institute for Health Metrics and Evaluation, a US-based public health research institute, 15% of individuals aged 30 and above had osteoarthritis in 2023, with the number of affected individuals projected to reach approximately 1 billion by 2050. Therefore, the rising incidence of chronic conditions is propelling the growth of the osteomyelitis market.

Major companies operating in the osteomyelitis market are focusing on developing innovative solutions, such as premixed intravenous (IV) formulations, to address antibiotic resistance and improve patient outcomes. Premixed intravenous (IV) formulations are ready-to-use sterile liquids containing specific drugs or electrolytes, designed to enhance safety and reduce preparation time in clinical settings. For instance, in September 2024, Hikma Pharmaceuticals Plc, a UK-based pharmaceutical company, launched a clindamycin injection formulated with 5% dextrose. This medication treats serious infections caused by susceptible anaerobic and gram-positive bacteria, including bone and joint infections such as acute hematogenous osteomyelitis. It provides a convenient, ready-to-use intravenous option, particularly for patients allergic to penicillin or in cases where penicillin is unsuitable.

In March 2024, BiomX Inc., an Israel-based biotechnology company, acquired Adaptive Phage Therapeutics Inc. for an undisclosed sum. Through this acquisition, BiomX aims to become a leading phage therapy company with an advanced pipeline targeting Phase 2 assets for treating chronic pulmonary infections in cystic fibrosis and diabetic foot osteomyelitis. Adaptive Phage Therapeutics Inc., a US-based biotechnology company, develops phage therapies specifically for osteomyelitis, with a focus on diabetic foot infections.

Major companies operating in the osteomyelitis market are Pfizer Inc, Johnson and Johnson, F Hoffmann La Roche Ltd, Sanofi SA, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Otsuka Pharmaceutical Co Ltd, Fresenius Kabi AG, Sumitomo Pharma Company Limited, Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd, Torrent Pharmaceuticals Ltd, Basilea Pharmaceutica Ltd, Paratek Pharmaceuticals Inc, Debiopharm International SA, Accord Healthcare Limited, Melinta Therapeutics LLC, Cempra Inc, MicuRx Pharmaceuticals Inc, Durata Therapeutics Inc.

North America was the largest region in the osteomyelitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the osteomyelitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the osteomyelitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the osteomyelitis market by increasing costs of imported antibiotics, antifungal agents, diagnostic imaging equipment, and surgical consumables used in infection management. Hospitals and clinics in North America and Europe are most affected due to reliance on imported pharmaceutical ingredients and medical devices, while Asia-Pacific faces higher costs related to drug formulation and diagnostic supplies. These tariffs are contributing to higher treatment expenses and procurement delays. However, they are also encouraging domestic drug manufacturing, local antibiotic production, and regional diagnostic infrastructure development.

The osteomyelitis market research report is one of a series of new reports that provides osteomyelitis market statistics, including osteomyelitis industry global market size, regional shares, competitors with a osteomyelitis market share, detailed osteomyelitis market segments, market trends and opportunities, and any further data you may need to thrive in the osteomyelitis industry. This osteomyelitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Osteomyelitis is an infection and inflammation of the bone, typically caused by bacteria or fungi that spread through the bloodstream or from nearby tissue. The condition can lead to bone destruction and impaired blood flow. Common symptoms include bone pain, fever, swelling, and sometimes pus drainage.

The primary types of osteomyelitis include medullary osteomyelitis, superficial osteomyelitis, and others. Medullary osteomyelitis refers to infection primarily localized in the bone marrow cavity, often hematogenous in origin and most commonly caused by Staphylococcus aureus. Treatments involve drug types such as antibiotics, antifungals, and non-steroidal anti-inflammatory drugs (NSAIDs), administered orally or parenterally. These medications are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, serving end users including hospitals, clinics, research organizations, and diagnostic centers. This structured approach ensures effective management and accessibility of osteomyelitis treatments.

The osteomyelitis market consists of revenues earned by entities by providing services such as diagnostic imaging services, surgical debridement, infection control, antimicrobial therapy, hospitalization, post-operative rehabilitation, and long-term care management. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteomyelitis market also includes sales of antibiotic-loaded bone cement, bone graft materials, orthopedic implants, wound care products, diagnostic kits, and surgical instruments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.